Residency · Residency · Chronic Pain Management

Opioid Use Disorder in Chronic Pain Patients

Introduction

Opioid use disorder (OUD) is a chronic, relapsing neurobiological condition characterized by compulsive opioid use despite harmful consequences. In the chronic pain population, OUD presents unique diagnostic and therapeutic challenges because many of its behavioral features overlap with undertreated pain (sometimes called pseudoaddiction), physical dependence, and tolerance. Systematic reviews estimate the prevalence of OUD in chronic pain patients receiving long-term opioid therapy at 8-12% by strict diagnostic criteria, with rates of aberrant drug-related behaviors substantially higher. Integrating addiction medicine principles into pain practice is essential for identifying and treating OUD without abandoning patients who have legitimate pain needs.

Diagnosis: DSM-5 Criteria

The DSM-5 defines opioid use disorder as a problematic pattern of opioid use leading to clinically significant impairment or distress, manifested by at least 2 of 11 criteria within a 12-month period. These criteria fall into four domains.

Impaired Control

The first domain encompasses taking opioids in larger amounts or over a longer period than intended, persistent desire or unsuccessful efforts to cut down, spending a great deal of time obtaining, using, or recovering from opioids, and craving or a strong desire to use opioids.

Social Impairment

The second domain includes recurrent opioid use resulting in failure to fulfill major role obligations at work, school, or home; continued use despite persistent social or interpersonal problems caused or exacerbated by opioids; and giving up or reducing important social, occupational, or recreational activities because of opioid use.

Risky Use

The third domain covers recurrent opioid use in physically hazardous situations and continued use despite knowledge of a persistent physical or psychological problem likely caused or exacerbated by opioids.

Pharmacological Indicators

The fourth domain includes tolerance and withdrawal -- but with a critical caveat. Tolerance and withdrawal that develop during appropriately prescribed opioid therapy are expected pharmacologic phenomena and should not be counted toward a diagnosis of OUD in patients taking opioids as prescribed. This distinction is fundamental and frequently misunderstood.

Severity Classification

Severity is graded by the number of criteria met: mild (2-3 criteria), moderate (4-5 criteria), or severe (6 or more criteria).

<image>Diagnostic framework diagram showing the 11 DSM-5 criteria for opioid use disorder organized into four domains (impaired control, social impairment, risky use, pharmacological indicators), with visual indicators highlighting which criteria overlap with normal chronic pain treatment behaviors (tolerance, withdrawal) and which are specific to OUD (compulsive use, craving, continued use despite harm)</image>

Prevalence in Pain Populations

Systematic reviews place the prevalence of OUD in chronic pain patients on long-term opioid therapy at 8-12%. Aberrant drug-related behaviors, which are not equivalent to OUD, occur in approximately 20-30% of chronic pain patients. Risk factors for developing OUD in the pain population include a personal or family history of substance use disorders, history of psychiatric disorders (depression, anxiety, PTSD), younger age, higher prescribed opioid doses, history of childhood adversity or trauma, and concurrent use of benzodiazepines or other sedatives.

Screening Tools

Several validated screening instruments are available. The Opioid Risk Tool (ORT) is a brief self-report screening for OUD risk used before initiating opioid therapy. The Screener and Opioid Assessment for Patients with Pain (SOAPP-R) is a 24-item tool that predicts aberrant drug-related behaviors. The Current Opioid Misuse Measure (COMM) monitors ongoing misuse in patients already on opioid therapy. The CAGE-AID is an adapted version of the CAGE questionnaire for alcohol and drug use. No screening tool is definitive on its own; clinical judgment informed by behavioral observation remains essential.

Differentiating OUD from Pseudoaddiction and Undertreated Pain

Pseudoaddiction

Pseudoaddiction is a term describing drug-seeking behavior driven by inadequately treated pain rather than addiction. In theory, the behaviors resolve when pain is adequately treated. However, this concept is controversial and has been misused to justify inappropriate opioid dose escalation. Clinicians should approach the distinction with caution and should not automatically assume that all aberrant behavior is pseudoaddiction.

Key Distinguishing Features

In OUD, patients continue compulsive use even when pain is controlled or despite worsening function. They demonstrate loss of control over use, escalation beyond prescribed parameters, and use for euphoria rather than analgesia. Functional decline across multiple domains (social, occupational, self-care) despite or because of opioid use supports an OUD diagnosis. By contrast, patients with undertreated pain typically demonstrate improvement in function when pain is better managed.

Medication-Assisted Treatment (MAT)

Buprenorphine

Buprenorphine is the first-line treatment for OUD in chronic pain patients because of its dual efficacy for both addiction and pain. As a partial mu agonist, it provides opioid receptor stabilization without the full agonist euphoria. The typical maintenance dose for OUD is 8-24 mg/day sublingually, and it can now be prescribed in office-based settings without an X-waiver (since January 2023). Buprenorphine reduces illicit opioid use, overdose mortality, and criminal activity. Its analgesic effects may require supplementation with non-opioid analgesics, but this is generally manageable.

Naltrexone

Naltrexone is a full opioid antagonist available as an oral tablet (50 mg daily) or an extended-release intramuscular injection (Vivitrol, 380 mg monthly). It blocks opioid receptors, preventing euphoria from exogenous opioids. Because it requires 7-14 days of opioid abstinence before initiation to avoid precipitated withdrawal, it is not suitable for patients who need ongoing opioid analgesia. It may, however, be appropriate for patients whose chronic pain can be managed with non-opioid therapies and who have comorbid OUD. The extended-release injection improves adherence compared to the oral formulation.

Methadone for OUD

Methadone for OUD is prescribed through federally licensed opioid treatment programs (OTPs) and provides opioid receptor stabilization, reduces cravings, and prevents withdrawal. It also provides analgesia, making it useful for patients with coexisting pain and OUD. Methadone for OUD requires daily observed dosing initially, with take-home privileges earned over time. Coordination between the OTP and the patient's pain provider is essential.

<image>Comparative treatment table illustrated as a medical infographic showing the three FDA-approved medications for OUD (buprenorphine, naltrexone, methadone), comparing their receptor pharmacology, route of administration, prescribing setting requirements, suitability for concurrent chronic pain, key advantages, and main limitations, organized in parallel columns with visual receptor binding diagrams at top</image>

Integration of Addiction Medicine into Pain Practice

Universal Precautions Approach

The universal precautions model applies consistent monitoring practices to all patients on opioid therapy, not only those with identified risk factors. This approach reduces stigma and ensures systematic screening. Its components include informed consent, treatment agreements, urine drug testing, PDMP review, functional assessments, and regular follow-up.

Monitoring Strategies

Urine drug testing (UDT) should be obtained at baseline and randomly during treatment, testing both for prescribed medications (confirming adherence) and non-prescribed substances. The Prescription Drug Monitoring Program (PDMP) should be checked at every visit and before every prescription. Random pill counts verify remaining medication supply. Behavioral assessments monitor for early refill requests, dose escalation demands, reports of lost or stolen medications, and functional decline.

Collaborative Care Model

Effective management requires clear co-management protocols between pain medicine and addiction medicine specialists. Behavioral health providers (psychologists, social workers) should be integrated into the pain team. When OUD is identified, a warm handoff process -- rather than abrupt discharge from the pain practice -- is both ethically and clinically necessary. Discontinuing opioids without providing alternative treatment or referral constitutes patient abandonment and is dangerous, as it increases the risk of illicit opioid use, overdose, and death.

Addressing Stigma

OUD is a chronic medical condition, not a moral failing, and language matters. Person-first language ("patient with opioid use disorder" rather than "addict" or "drug seeker") is the standard. Patients with OUD and chronic pain deserve comprehensive treatment for both conditions. Training in motivational interviewing improves the therapeutic alliance and treatment engagement.

<image>Workflow diagram showing the integration of addiction medicine screening and treatment into a chronic pain clinic visit, starting with pre-visit PDMP review, through standardized screening tools, clinical assessment for OUD criteria, urine drug testing, decision nodes for identified OUD versus no OUD, and branching pathways to in-house buprenorphine initiation, referral to addiction medicine, or continued standard pain management with ongoing monitoring</image>

Clinical Pearls

Tolerance and withdrawal during prescribed opioid therapy are pharmacologic phenomena and should not count toward an OUD diagnosis; the behavioral and functional criteria are what matter. The Opioid Risk Tool and SOAPP-R are useful for risk stratification but do not diagnose OUD -- clinical assessment using DSM-5 criteria remains the gold standard. Buprenorphine is the ideal medication for patients with both chronic pain and OUD, providing receptor stabilization for addiction while maintaining analgesia. Abruptly discontinuing opioids in a patient suspected of having OUD without offering medication-assisted treatment or referral increases the risk of illicit opioid use, overdose, and death. Universal precautions (UDT, PDMP, treatment agreements) applied to all patients reduce stigma and improve systematic detection of OUD.

References

1. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569-576.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
3. Manhapra A, Arias AJ, Ballantyne JC. The conundrum of opioid tapering in long-term opioid therapy for chronic pain: a commentary. Substance Abuse. 2018;39(2):152-161.
4. Substance Abuse and Mental Health Services Administration. TIP 63: Medications for Opioid Use Disorder. HHS Publication No. (SMA) 18-5063. Rockville, MD: SAMHSA; 2021.

Read this lecture as Markdown